Elemer Piros analyst BENCHMARK

Currently out of the existing stock ratings of Elemer Piros, 148 are a BUY (84.09%), 15 are a HOLD (8.52%), 13 are a SELL (7.39%).

Elemer Piros

Work Performance Price Targets & Ratings Chart

Analyst Elemer Piros, currently employed at BENCHMARK, carries an average stock price target met ratio of 45.53% that have a potential upside of 40.78% achieved within 228 days. Previously, Elemer Piros worked at ROTH.

Elemer Piros’s has documented 335 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARWR, Arrowhead Pharmaceuticals at 08-Aug-2023.

Wall Street Analyst Elemer Piros

Analyst best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for ARCT (ARCTURUS THERAPEUTICS HOLDINGS) at 3/2/2021. The price target of $45 was fulfilled within 3 days with a profit of $8.96 (16.6%) receiving and performance score of 55.35.

Average potential price target upside

ABEO Abeona Therapeutics AERI Aerie Pharmaceuticals . APLS Apellis Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CMPS Compass Pathways Plc CRBP Corbus Pharmaceuticals DMAC DiaMedica Therapeutics DVAX Dynavax Technologies GKOS Glaukos Corp GWPH GW Pharmaceuticals plc HEPA Hepion Pharmaceuticals OCUL Ocular Therapeutix OMER Omeros ONCE Spark Therapeutics UBX Unity Biotechnology ZYNE Zynerba Pharmaceuticals GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals ALDX Aldeyra The ARCT Arcturus Therapeutics Holdings ATAI ATAI Life Sciences BV PTE Polarityte CLNN Clene . MNMD Mind Medicine  AUPH Aurinia Pharmaceuticals BLCM Bellicum Pharmaceuticals BRTX BioRestorative Therapies CYBN Cybin  DMTTF Small Pharma FOLD Amicus Therapeutics GHRS GH Research PLC GLMD Galmed Pharmaceuticals Ltd MNPR Monopar Therapeutics QURE Uniqure NV UNCY Unicycive Therapeutics KTTA Pasithea Therapeutics Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$9.14 (155.97%)

$15

20 days ago
(31-Oct-2024)

0/5 (0%)

$8.59 (134.01%)

Buy

$18

$12.14 (207.17%)

$18

22 days ago
(29-Oct-2024)

1/6 (16.67%)

$11.43 (173.97%)

61

Hold

$6

$0.14 (2.39%)

$5

2 years 6 days ago
(14-Nov-2022)

2/3 (66.67%)

$1.85 (44.58%)

257

Buy

$75

$70.79 (1681.47%)

$50

4 years 9 days ago
(11-Nov-2020)

2/3 (66.67%)

$45.92 (117.11%)

101

Buy

$22

4 years 6 months 12 days ago
(08-May-2020)

1/3 (33.33%)

$-59.25 (-72.92%)

820

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Elemer Piros?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?